New
HealthMore in Health →
CSL hit by revenue warning and $5 billion impairment as shares slide to a nine-year low
CSL cut full-year revenue guidance by about 4% and disclosed a new $5 billion impairment charge, sending its stock to its lowest level since early 2017.
Key Takeaways
- CSL reduced its full-year revenue guidance by roughly 4%.
- The company will take a new $5 billion impairment charge.
DE
DT Editorial AI··via endpoints.news